# EDGAR Filing Document

**Accession Number:** 0002012593
**File Stem:** 0001104659-25-091350
**Filing Date:** 2025-9
**Character Count:** 31708
**Document Hash:** 4b08d8dc1bb214b26673e703d965eedf
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001104659-25-091350.hdr.sgml**: 20250918

**ACCESSION NUMBER**: 0001104659-25-091350

**CONFORMED SUBMISSION TYPE**: SCHEDULE 13D/A

**PUBLIC DOCUMENT COUNT**: 3

**FILED AS OF DATE**: 20250918

**DATE AS OF CHANGE**: 20250918

**SUBJECT COMPANY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Rapport Therapeutics, Inc.
- **CENTRAL INDEX KEY:** 0002012593
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 880724208
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** SCHEDULE 13D/A
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 005-94532
- **FILM NUMBER:** 251324444

**BUSINESS ADDRESS:**
- **STREET 1:** 99 HIGH STREET
- **STREET 2:** SUITE 2100
- **CITY:** BOSTON
- **STATE:** MA
- **ZIP:** 02110
- **BUSINESS PHONE:** 857-321-8020

**MAIL ADDRESS:**
- **STREET 1:** 99 HIGH STREET
- **STREET 2:** SUITE 2100
- **CITY:** BOSTON
- **STATE:** MA
- **ZIP:** 02110
**FILED BY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Sofinnova Venture Partners XI, L.P.
- **CENTRAL INDEX KEY:** 0001882303

**ORGANIZATION NAME:**
- **EIN:** 000000000
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** SCHEDULE 13D/A

**BUSINESS ADDRESS:**
- **STREET 1:** 3000 SAND HILL ROAD, 4-250
- **CITY:** MENLO PARK
- **STATE:** CA
- **ZIP:** 94025
- **BUSINESS PHONE:** 650-681-8420

**MAIL ADDRESS:**
- **STREET 1:** 3000 SAND HILL ROAD, 4-250
- **CITY:** MENLO PARK
- **STATE:** CA
- **ZIP:** 94025

## Ex-99.A

<u>exhibit A</u>

<u>Agreement of Joint Filing</u>

The undersigned hereby agree that a single Schedule 13D (or any amendment thereto) relating to the Common Stock of Rapport Therapeutics, Inc. shall be filed on behalf of each of the undersigned and that this Agreement shall be filed as an exhibit to such Schedule 13D.

Date: June 13, 2024

---

| | |
|:---|:---|
| SOFINNOVA VENTURE PARTNERS XI, L.P., a Delaware Limited Partnership | SOFINNOVA VENTURE PARTNERS XI, L.P., a Delaware Limited Partnership |
| By: | SOFINNOVA MANAGEMENT XI, L.P., a Delaware Limited Partnership |
| Its: General Partner | Its: General Partner |
| By: | SOFINNOVA MANAGEMENT XI, L.L.C., a Delaware Limited Liability Company |
| Its: | General Partner |
| By: | /s/ Nathalie Auber |
|  | Nathalie Auber |
|  | Attorney-in-Fact |
| SOFINNOVA MANAGEMENT XI, L.P., a Delaware Limited Partnership | SOFINNOVA MANAGEMENT XI, L.P., a Delaware Limited Partnership |
| By: | SOFINNOVA MANAGEMENT XI, L.L.C., a Delaware Limited Liability Company |
| Its: | General Partner |
| By: | /s/ Nathalie Auber |
|  | Nathalie Auber |
|  | Attorney-in-Fact |
| SOFINNOVA MANAGEMENT XI, L.L.C., a Delaware Limited Liability Company | SOFINNOVA MANAGEMENT XI, L.L.C., a Delaware Limited Liability Company |
| By: | /s/ Nathalie Auber |
|  | Nathalie Auber |
|  | Attorney-in-Fact |
| DR. JAMES I. HEALY | DR. JAMES I. HEALY |
| DR. MAHA KATABI | DR. MAHA KATABI |
| By: | /s/ Nathalie Auber |
|  | Nathalie Auber |
|  | Attorney-in-Fact |

---

## Ex-99.B

<u>exhibit B</u>

<u>Power of Attorney</u>

Each of the undersigned entities and individuals (collectively, the "Reporting Persons") hereby authorizes and designates Sofinnova Management XI, L.L.C. or such other person or entity as is designated in writing by James I. Healy (the "Designated Filer") as the beneficial owner to prepare and file on behalf of such Reporting Person individually, or jointly together with the other Reporting Persons, any and all reports, notices, communications and other documents (including, but not limited to, reports on Schedule 13D, Schedule 13G, Form 3, Form 4 and Form 5) that such Reporting Person may be required to file with the United States Securities and Exchange Commission pursuant to the Securities Act of 1933, as amended (together with the implementing regulations thereto, the "Act") and the Securities Exchange Act of 1934, as amended (together with the implementing regulations thereto, the "Exchange Act") (collectively, the "Reports") with respect to each Reporting Person's ownership of, or transactions in, securities of any entity whose securities are beneficially owned (directly or indirectly) by such Reporting Person (collectively, the "Companies").

Each Reporting Person hereby further authorizes and designates Nathalie Auber (the "Authorized Signatory") to execute and file on behalf of such Reporting Person the Reports and to perform any and all other acts, which in the opinion of the Designated Filer or Authorized Signatory may be necessary or incidental to the performance of the foregoing powers herein granted.

The authority of the Designated Filer and the Authorized Signatory under this Document with respect to each Reporting Person shall continue until such Reporting Person is no longer required to file any Reports with respect to the Reporting Person's ownership of, or transactions in, the securities of the Companies, unless earlier revoked in writing. Each Reporting Person acknowledges that the Designated Filer and the Authorized Signatory are not assuming any of the Reporting Person's responsibilities to comply with the Act or the Exchange Act.

Date: September 10, 2021

---

| | |
|:---|:---|
| SOFINNOVA VENTURE PARTNERS XI, L.P. | SOFINNOVA VENTURE PARTNERS XI, L.P. |
| a Delaware Limited Partnership | a Delaware Limited Partnership |
| By: | Sofinnova Management XI, L.P. |
|  | a Delaware Limited Partnership |
|  | Its General Partner |
| By: | Sofinnova Management XI, L.L.C. |
|  | a Delaware Limited Liability Company |
|  | Its General Partner |
| By: | /s/ James I. Healy |
|  | James I. Healy |
|  | Managing Member |
| SOFINNOVA MANAGEMENT XI, L.P. | SOFINNOVA MANAGEMENT XI, L.P. |
| a Delaware Limited Partnership | a Delaware Limited Partnership |
| By: | Sofinnova Management XI, L.L.C. |
|  | a Delaware Limited Liability Company |
|  | Its General Partner |
| By: | /s/ James I. Healy |
|  | James I. Healy |
|  | Managing Member |
| SOFINNOVA MANAGEMENT XI, L.L.C. | SOFINNOVA MANAGEMENT XI, L.L.C. |
| a Delaware Limited Liability Company | a Delaware Limited Liability Company |
| By: | /s/ James I. Healy |
|  | James I. Healy |
|  | Managing Member |
| JAMES I. HEALY | JAMES I. HEALY |
| By: | /s/ James I. Healy |
|  | James I. Healy |
| MAHA KATABI | MAHA KATABI |
| By: | /s/ Maha Katabi |
|  | Maha Katabi |

---

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## SCHEDULE 13D

### Under the Securities Exchange Act of 1934

**(Amendment No. 1)**

**Rapport Therapeutics, Inc.**

*(Name of Issuer)*

**Common Stock, $0.001 par value**

*(Title of Class of Securities)*

**75383L102**

*(CUSIP Number)*

**Nathalie Auber**<br>Sofinnova Investments, Inc.<br>3000 Sand Hill Road, Bldg 3, Suite 150<br>Menlo Park CA 94025<br>(650) 681-8420

*(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)*

**09/11/2025**

*(Date of Event Which Requires Filing of this Statement)*

| **CUSIP No.** | **75383L102** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**Sofinnova Venture Partners XI, L.P. ("SVP XI")** | Name of reporting person<br>**Sofinnova Venture Partners XI, L.P. ("SVP XI")** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[ ] (a)<br>[x] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[ ] (a)<br>[x] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**WC** | Source of funds (See Instructions)<br>**WC** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**DELAWARE** | Citizenship or place of organization<br>**DELAWARE** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**1863327.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**1863327.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**0.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**1863327.00** | Aggregate amount beneficially owned by each reporting person<br>**1863327.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**4.0%** | Percent of class represented by amount in Row (11)<br>**4.0%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**PN** | Type of Reporting Person (See Instructions)<br>**PN** | |

---

**Comment for Reporting Person:** Note to Row 7:  1,863,327 shares, except that Sofinnova Management XI, L.P. ("SM XI LP"), the general partner of SVP XI may be deemed to have sole voting power, Sofinnova Management XI, L.L.C. ("SM XI LLC"), the general partner of SM XI LP, may be deemed to have sole voting power, and Dr. James I. Healy ("Healy") and Dr. Maha Katabi ("Katabi"), the managing members of SM XI LLC, may be deemed to have shared power to vote these shares.

Note to Row 8: See response to row 7.

Note to Row 9:  1,863,327 shares, except that SM XI LP, the general partner of SVP XI, may be deemed to have sole dispositive power, SM XI LLC, the general partner of SM XI LP, may be deemed to have sole dispositive power and Healy and Katabi, the managing members of SM XI LLC, may be deemed to have shared dispositive power over these shares.

Note to Row 10: See response to row 9.

| **CUSIP No.** | **75383L102** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**Sofinnova Management XI, L.P. ("SM XI LP")** | Name of reporting person<br>**Sofinnova Management XI, L.P. ("SM XI LP")** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[ ] (a)<br>[x] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[ ] (a)<br>[x] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**AF** | Source of funds (See Instructions)<br>**AF** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**DELAWARE** | Citizenship or place of organization<br>**DELAWARE** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**1863327.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**1863327.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**0.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**1863327.00** | Aggregate amount beneficially owned by each reporting person<br>**1863327.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**4.0%** | Percent of class represented by amount in Row (11)<br>**4.0%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**PN** | Type of Reporting Person (See Instructions)<br>**PN** | |

---

**Comment for Reporting Person:** Note to Row 7: 1,863,327 shares, all of which are owned directly by SVP XI.  SM XI LP, the general partner of SVP XI, may be deemed to have sole voting power, SM XI LLC, the general partner of SM XI LP, may be deemed to have sole voting power, and Healy and Katabi, the managing members of SM XI LLC, may be deemed to have shared power to vote these shares.

Note to Row 8: See response to row 7.

Note to Row 9: 1,863,327 shares, all of which are owned directly by SVP XI.  SM XI LP, the general partner of SVP XI, may be deemed to have sole dispositive power, SM XI LLC, the general partner of SM XI LP, may be deemed to have sole dispositive power, and Healy and Katabi, the managing members of SM XI LLC, may be deemed to have shared dispositive power over these shares.

Note to Row 10: See response to row 9.

| **CUSIP No.** | **75383L102** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**Sofinnova Management XI, L.L.C. ("SM XI LLC")** | Name of reporting person<br>**Sofinnova Management XI, L.L.C. ("SM XI LLC")** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[ ] (a)<br>[x] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[ ] (a)<br>[x] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**AF** | Source of funds (See Instructions)<br>**AF** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**DELAWARE** | Citizenship or place of organization<br>**DELAWARE** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**1863327.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**1863327.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**0.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**1863327.00** | Aggregate amount beneficially owned by each reporting person<br>**1863327.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**4.0%** | Percent of class represented by amount in Row (11)<br>**4.0%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**OO** | Type of Reporting Person (See Instructions)<br>**OO** | |

---

**Comment for Reporting Person:** Note to Row 7:  1,863,327 shares, all of which are owned directly by SVP XI.  SM XI LP, the general partner of SVP XI, may be deemed to have sole voting power, SM XI LLC, the general partner of SM XI LP, may be deemed to have sole voting power, and Healy and Katabi, the managing members of SM XI LLC, may be deemed to have shared power to vote these shares.

Note to Row 8: See response to row 7.

Note to Row 9:  1,863,327 shares, all of which are owned directly by SVP XI.  SM XI LP, the general partner of SVP XI, may be deemed to have sole dispositive power, SM XI LLC, the general partner of SM XI LP, may be deemed to have sole dispositive power, and Healy and Katabi, the managing members of SM XI LLC, may be deemed to have shared dispositive power over these shares.

Note to Row 10: See response to row 9.

| **CUSIP No.** | **75383L102** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**Dr. James I. Healy ("Healy")** | Name of reporting person<br>**Dr. James I. Healy ("Healy")** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[ ] (a)<br>[x] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[ ] (a)<br>[x] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**AF** | Source of funds (See Instructions)<br>**AF** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**X1** | Citizenship or place of organization<br>**X1** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**4822.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**1947579.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**4822.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**1947579.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**1947579.00** | Aggregate amount beneficially owned by each reporting person<br>**1947579.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**4.2%** | Percent of class represented by amount in Row (11)<br>**4.2%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**IN** | Type of Reporting Person (See Instructions)<br>**IN** | |

---

**Comment for Reporting Person:** Note to Row 7: 4,822 shares

Note to Row 8: 1,947,579 shares, 1,863,327 of which are owned directly by SVP XI, 22,894 of which are owned directly by SummitTX Master, SPC -SummitTX Apex SP - Healthcare 3 ("Apex SP") (f/k/a Crestline Summit Master, SPC - Crestline Summit Apex SP), 23,643 of which are owned directly by SummitTX Master, SPC - SummitTX Alpha SP - Healthcare 3 ("Alpha SP") (f/k/a Crestline Summit Master, SPC - PEAK SP) and 37,715 of which are owned directly by SummitTX Pinnacle Master, L.P. - Healthcare 3 ("Pinnacle LP") (f/k/a Crestline Summit Pinnacle Master, L.P.).  SM XI LP, the general partner of SVP XI, and SM XI LLC, the general partner of SM XI LP, may be deemed to have sole voting power over the shares owned by SVP XI, and Healy, a managing member of SM XI LLC, and a director of the Issuer, may be deemed to have shared power to vote these shares.  Sofinnova Synergy Fund GP, LLC ("Synergy GP"), the general partner of each of Apex SP, Alpha SP and Pinnacle LP, may be deemed to have sole voting power over the shares owned by Apex SP, Alpha SP and Pinnacle LP, and Healy, a managing member of Synergy GP, may be deemed to have shared power to vote these shares.

Note to Row 9: 4,822 shares

Note to Row 10: See Row 91,947,579 shares, 1,863,327 of which are owned directly by SVP XI, 22,894 of which are owned directly by Apex SP, 23,643 of which are owned directly by Alpha SP and 37,715 of which are owned directly Pinnacle LP.  SM XI LP, the general partner of SVP XI, and SM XI LLC, the general partner of SM XI LP, may be deemed to have sole dispositive power over the shares owned by SVP XI, and Healy, a managing member of SM XI LLC, and a director of the Issuer, may be deemed to have shared dispositive power over these shares.  Synergy GP, the general partner of each of Apex SP, Alpha SP and Pinnacle LP, may be deemed to have sole dispositive power over the shares owned by Apex SP, Alpha SP and Pinnacle LP, and Healy, a managing member of Synergy GP, may be deemed to have shared dispositive power over these shares.

| **CUSIP No.** | **75383L102** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**Dr. Maha Katabi ("Katabi")** | Name of reporting person<br>**Dr. Maha Katabi ("Katabi")** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[ ] (a)<br>[x] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[ ] (a)<br>[x] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**AF** | Source of funds (See Instructions)<br>**AF** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**ISRAEL** | Citizenship or place of organization<br>**ISRAEL** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**1863327.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**1863327.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**1863327.00** | Aggregate amount beneficially owned by each reporting person<br>**1863327.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**4.0%** | Percent of class represented by amount in Row (11)<br>**4.0%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**IN** | Type of Reporting Person (See Instructions)<br>**IN** | |

---

**Comment for Reporting Person:** Note to Row 7: 0

Note to Row 8: 1,863,327 shares, all of which are owned directly by SVP XI.  SM XI LP, the general partner of SVP XI, may be deemed to have sole voting power, SM XI LLC, the general partner of SM XI LP, may be deemed to have sole voting power, and Katabi, a managing member of SM XI LLC, may be deemed to have shared power to vote these shares.

Note to Row 9: 0

Note to Row 10: 1,863,327 shares, all of which are owned directly by SVP XI.  SM XI LP, the general partner of SVP XI, may be deemed to have sole dispositive power, SM XI LLC, the general partner of SM XI LP, may be deemed to have sole dispositive power, and Katabi, a managing member of SM XI LLC, may be deemed to have shared dispositive power over these shares.

**Item 1. Security and Issuer**

**(a) Title of Class of Securities:**
Common Stock, $0.001 par value

**(b) Name of Issuer:**
Rapport Therapeutics, Inc.

**(c) Address of Issuer's Principal Executive Offices:**
99 High Street, Suite 2100, Boston, MA, 02110

This Amendment No. 1 ("Amendment No. 1") amends and restates the Statement on Schedule 13D that was originally filed on June 14, 2024 (the "Original Schedule 13D").  This Amendment No. 1 relates to the beneficial ownership of Common Stock, $0.001 par value per share ("Common Stock") of Rapport Therapeutics, Inc., a Delaware corporation ("Issuer") and is being filed by Sofinnova Venture Partners XI, L.P., a Delaware limited partnership ("SVP XI"), Sofinnova Management XI, L.P., a Delaware limited partnership ("SM XI LP"), Sofinnova Management XI, L.L.C., a Delaware limited liability company ("SM XI LLC"), Dr. James I. Healy ("Healy"), and Dr. Maha Katabi ("Katabi" and collectively with SVP XI, SM XI LP, SM XI LLC, and Healy, the "Reporting Persons").  This Amendment No. 1 is being filed to reflect that the Reporting Persons ceased to be beneficial owners of more than five percent (5%) of the Issuer's Common Stock due to dilution caused by the Issuer's sales of additional shares of its Common Stock from time to time since the filing of the Original Schedule 13D.

**Item 4. Purpose of Transaction**

The Reporting Persons hold their securities of the Issuer for investment purposes.  Depending on the factors discussed herein, the Reporting Persons may, from time to time, acquire additional Common Stock and/or retain and/or sell all or a portion of the Common Stock held by the Reporting Persons in the open market or in privately negotiated transactions, and/or may distribute the Common Stock held by the Reporting Persons to their respective members or limited partners.  Any actions the Reporting Persons might undertake will be dependent upon the Reporting Persons' review of numerous factors, including, among other things, the price levels of the Common Stock, general market and economic conditions, ongoing evaluation of the Issuer's business, financial condition, operations and prospects; the relative attractiveness of alternative business and investment opportunities, and other future developments.  Except as set forth above, the Reporting Persons have no present plans or intentions which would result in or relate to any of the transactions described in subparagraphs (a) through (j) of Item 4 of Schedule 13D.

**Item 5. Interest in Securities of the Issuer**

**(a)**
Regarding aggregate beneficial ownership, see Row 11 of the cover page of each Reporting Person.  Regarding percentage beneficial ownership, see Row 13 of the cover page of each Reporting Person.  Regarding sole power to vote shares, see Row 7 of the cover page of each Reporting Person.  Regarding shared power to vote shares, see Row 8 of the cover page of each Reporting Person.  Regarding sole power to dispose of shares, see Row 9 of the cover page of each Reporting Person.  Regarding shared power to dispose of shares, see Row 10 of the cover page of each Reporting Person.  The percentage listed in Row 13 for each Reporting Person was calculated based upon 46,113,062 shares of Common Stock outstanding immediately after an offering by the Issuer, as reported in the Issuer's Form 424B5 (File No. 333-288444) filed on September 10, 2025.

**(b)**
Regarding aggregate beneficial ownership, see Row 11 of the cover page of each Reporting Person.  Regarding percentage beneficial ownership, see Row 13 of the cover page of each Reporting Person.  Regarding sole power to vote shares, see Row 7 of the cover page of each Reporting Person.  Regarding shared power to vote shares, see Row 8 of the cover page of each Reporting Person.  Regarding sole power to dispose of shares, see Row 9 of the cover page of each Reporting Person.  Regarding shared power to dispose of shares, see Row 10 of the cover page of each Reporting Person.  The percentage listed in Row 13 for each Reporting Person was calculated based upon 46,113,062 shares of Common Stock outstanding immediately after an offering by the Issuer, as reported in the Issuer's Form 424B5 (File No. 333-288444) filed on September 10, 2025.

**(c)**
Except as set forth in Item 3 above, the Reporting Persons have not effected any transaction in the securities of the Issuer during the past 60 days.

**Item 6. Contracts, Arrangements, Understandings or Relationships With Respect to Securities of the Issuer.**

SVP XI and Healy have agreed that, without the prior written consent of Goldman Sachs & Co. LLC and Jefferies LLC, on behalf of the Issuer's underwriters, they will not, subject to limited exceptions, during the period ending 180 days after the date set forth on the Prospectus offer, sell, contract to sell, pledge, grant any option to purchase, loan, hedge, make any short sale or otherwise transfer or dispose of any shares of Common Stock, or any options or warrants to purchase any shares of Common Stock, or any securities convertible into, exchangeable for or that represent the right to receive shares of Common Stock, whether now owned or hereinafter acquired, owned directly (including holding as a custodian) or with respect to which they have beneficial ownership within the rules and regulations of the Securities and Exchange Commission.  Such Lock-Up Agreement is more fully described in the Prospectus and was filed as Annex II to Exhibit 1.1 to the Issuer's Form S-1 Registration Statement (File No. 333-279486), and such description is incorporated herein by reference.

SVP XI is a party to an Amended and Restated Investor Rights Agreement among the Issuer, SVP XI and other shareholders.  Subject to the terms of such Investors' Rights Agreement, SVP XI can demand that the Issuer file a registration statement or request that its Common Stock be covered by a registration statement that the Issuer is otherwise filing under certain specified circumstances.  Such Investors' Rights Agreement dated as of August 7, 2023 is more fully described in the Prospectus and was filed as Exhibit 4.2 to the Issuer's Form S-1 Registration Statement (File No. 333-279486), and such description is incorporated herein by reference.

Healy, in his capacity as a director of the Issuer, along with the other directors of the Issuer, entered into an Indemnification Agreement with the Issuer.  Such Indemnification Agreement is more fully described in the Prospectus and the form of such Indemnification Agreement was filed as Exhibit 10.4 to the Issuer's Amendment No. 1 to Form S-1 Registration Statement (File No. 333-279486), and such description is incorporated herein by reference.

SVP XI is a party to the Purchase Agreement and is entitled to certain registration rights.  If, following the one year anniversary of the date of effectiveness of the Issuer's Form S-1 Registration Statement, the shares issued to SVP XI in the Private Placement cannot be sold without restriction pursuant to Rule 144 of the Securities Act of 1933, as amended (the "Securities Act"), then upon SVP XI's request, received within 30 days of such anniversary, the Issuer has agreed to use commercially reasonable efforts to register such shares for resale on a registration statement on Form S-3 to be filed with the Securities and Exchange Commission.  The Purchase Agreement was filed as Exhibit 10.1 to the Issuer's Form 8-K (File No. 001-42121), and such description is incorporated herein by reference.

### SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** Sofinnova Venture Partners XI, L.P. ("SVP XI")

**Signature:** /s/ Nathalie Auber

**Name/Title:** Nathalie Auber/Attorney-in-Fact

**Date:** 09/17/2025

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** Sofinnova Management XI, L.P. ("SM XI LP")

**Signature:** /s/ Nathalie Auber

**Name/Title:** Nathalie Auber/Attorney-in-Fact

**Date:** 09/17/2025

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** Sofinnova Management XI, L.L.C. ("SM XI LLC")

**Signature:** /s/ Nathalie Auber

**Name/Title:** Nathalie Auber/Attorney-in-Fact

**Date:** 09/17/2025

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** Dr. James I. Healy ("Healy")

**Signature:** /s/ Nathalie Auber

**Name/Title:** Nathalie Auber/Attorney-in-Fact

**Date:** 09/17/2025

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** Dr. Maha Katabi ("Katabi")

**Signature:** /s/ Nathalie Auber

**Name/Title:** Nathalie Auber/Attorney-in-Fact

**Date:** 09/17/2025